科技圈🎗在花频道📮 | Telegram Webview: TestFlightCN/31944 -

科技圈🎗在花频道📮

过敏性鼻炎治疗研究取得新进展

2025年4月4日，首都医科大学附属北京同仁医院张罗教授团队在国际顶级期刊《自然·医学》（Nature Medicine）发表突破性研究成果——《司普奇拜单抗治疗中重度季节性过敏性鼻炎：一项随机3期试验》（Stapokibart for moderate-to-severe seasonal allergic rhinitis: a randomized phase 3 trial）。
这是全球范围内首次报告基于IL-4Rα靶点的生物制剂治疗季节性过敏性鼻炎的研究成果，亦是中国科学家在过敏性鼻炎领域取得的引领世界的创新性新成果。研究结果显示，司普奇拜单抗能够快速、强效控制患者的鼻部症状，持续显著缓解患者眼部过敏症状，极大提升患者生活质量，且安全性良好。

Nature Medicine

📮投稿 ☘️频道 🌸聊天

www.tg-me.com/sa/在花软件新闻投稿频道/com.TestFlightCN/31945

21.2K viewsApr 5 at 12:04

tg-me.com/TestFlightCN/31944

Create: 2025-04-05
Last Update: 2025-05-03 04:05:11

BY 科技圈🎗在花频道📮

Share with your friend now:
tg-me.com/TestFlightCN/31944

在花软件新闻投稿频道 Telegram | DID YOU KNOW?

Tata Power whose core business is to generate, transmit and distribute electricity has made no money to investors in the last one decade. That is a big blunder considering it is one of the largest power generation companies in the country. One of the reasons is the company's huge debt levels which stood at ₹43,559 crore at the end of March 2021 compared to the company’s market capitalisation of ₹44,447 crore.

The seemingly negative pandemic effects and resource/product shortages are encouraging and allowing organizations to innovate and change.The news of cash-rich organizations getting ready for the post-Covid growth economy is a sign of more than capital spending plans. Cash provides a cushion for risk-taking and a tool for growth.